Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HIC1
REST API REST API
Homo sapiens
HIC1 is differentially expressed in 221 experiments: 121 organism parts: bone marrow, cervix, ... (119 more);, 156 disease states: normal, acute myeloid leukemia, ... (154 more);, 61 cell types 291 cell lines 19 compound treatments and 72 other conditions.
Synonyms ZNF901, ZBTB29
Orthologs Hic1 (Mus musculus)   hic1 (Danio rerio)   HIC1 (Bos taurus)   D4A974_RAT (Rattus norvegicus)   hic1 (Xenopus laevis)   HIC1 (Canis familiaris)   (Compare orthologs)
InterPro Term Znf_C2H2-like, BTB_POZ, BTB/POZ-like, Znf_C2H2
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, intracellular, transcription, DNA-dependent, metal ion binding, multicellular organismal development, nucleus, zinc ion binding, sequence-specific DNA binding transcription factor activity
UniProt Accession Q14526, O95459
Search EB-eye ENSG00000177374
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-19639, E-MTAB-62, E-GEOD-4219, E-TABM-420, E-GEOD-1657, ... (26 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HL-60
2
E-GEOD-24147, E-MTAB-37
SW480
2
E-MEXP-1014, E-MTAB-37
COLO320HSR
1
E-MTAB-37
MCF-10A
1
E-TABM-420
GM13995
1
E-TABM-321
285 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (37 experiments)

Factor Value U/D Experiments
stromal cell
2
3
E-MEXP-2034, E-GEOD-1460, E-GEOD-3998, E-GEOD-10797, E-MEXP-1121 ... (5 experiments)
embryonic stem cell
1
E-MEXP-930
memory B cell
1
E-TABM-702
activated natural killer cell (supplemented for IL2 for 24 hours)
1
E-TABM-702
basal cell
1
E-GEOD-3998
monolayer
1
E-GEOD-4219
55 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-2508, E-GEOD-15960, E-GEOD-1869, ... (47 experiments)

Factor Value U/D Experiments
glioblastoma
2
E-MTAB-62, E-GEOD-4412
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
chronic lymphocytic leukemia
1
2
E-GEOD-2466, E-GEOD-6691, E-MTAB-37
replicate control
1
E-GEOD-21340
colorectal carcinoma
1
E-GEOD-23878
carcinoma in situ lesion
1
E-GEOD-3167
150 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-6907, E-GEOD-15205, E-GEOD-5679, E-GEOD-412, ... (12 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-412, E-TABM-868
AM580
1
1
E-GEOD-5679
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
TGF-Beta1
1
1
E-MEXP-2645
estradiol
1
E-GEOD-20081
TNF
1
E-GEOD-15205
13 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
not specified
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, E-TABM-321, ... (8 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-MEXP-1446

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-3720, E-MEXP-2069, E-MEXP-1648, ... (25 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-512

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, E-GEOD-2487 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-2115, E-MEXP-101, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Processing time: 0.364 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM